• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [23368 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2023     Health Information and Quality Authority (HIQA) Expansion of the childhood immunisation schedule to include varicella (chickenpox) vaccination: health technology assessment
2023     Health Technology Wales (HTW) Control contact lenses and spectacles for the treatment of myopia in children
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: virtual genes panels of pediatric cancers by NGS of somatic exome and transcriptome - evaluation report of an analysis developed by the RQDM]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: optical genome mapping - diagnosis and prognostic stratification of hematological malignancies]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: virtual care in general surgery]
2023     Scottish Health Technologies Group (SHTG) Priorities for the north imaging alliance
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: virtual care in hematology/oncology]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: asthma management in children and adults]
2023     Scottish Health Technologies Group (SHTG) The cost-effectiveness of the Scottish Hip Fracture Audit
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: virtual care in internal medicine]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: models for coordinating interhospital transfers in critical care]
2023     Scottish Health Technologies Group (SHTG) Capsule sponge technologies for the detection of Barrett’s oesophagus and early stage oesophageal cancer
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: virtual care in neurology]
2023     WorkSafeBC Causal association between SARS-Cov-2 infection and the development of trigeminal neuralgia
2023     Scottish Health Technologies Group (SHTG) Technology-enabled theatre scheduling systems
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: virtual care in pediatrics]
2023     WorkSafeBC Causal association between carpal tunnel release surgery and trigger finger
2023     Scottish Health Technologies Group (SHTG) Digital prevention programme for people at risk of type 2 diabetes
2023     National Institute for Health and Care Excellence (NICE) Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes. NICE technology appraisal guidance 943
2023     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Trends in utilisation of ultrasound by older Australians (2010-2019)
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: virtual care in respirology]
2023     WorkSafeBC Platelet rich plasma in treating (recurrent) anterior shoulder dislocation
2023     National Institute for Health and Care Excellence (NICE) Empagliflozin for treating chronic kidney disease. NICE technology appraisal guidance 942
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: virtual care in psychiatry]
2023     WorkSafeBC Esketamine as treatment for depression and PTSD
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: assessment of Intercept and Mirasol - pathogen reduction technologies for the treatment of labile blood products in Quebec]
2023     National Institute for Health and Care Excellence (NICE) Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder (terminated appraisal). NICE technology appraisal guidance 941
2023     WorkSafeBC Botulinum toxin as treatment for neck strains
2023     National Institute for Health and Care Excellence (NICE) Ravulizumab for treating generalised myasthenia gravis (terminated appraisal). NICE technology appraisal guidance 940
2023     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Sutimlimab (cold agglutinin disease)]
2023     WorkSafeBC Migraines and the (Moderna) COVID-19 vaccine
2023     National Institute for Health and Care Excellence (NICE) Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer. NICE technology appraisal guidance 939
2023     WorkSafeBC Causal association between COVID-19 infection and irritable larynx syndrome
2023     National Institute for Health and Care Excellence (NICE) Dupilumab for treating eosinophilic oesophagitis in people 12 years and over (terminated appraisal). NICE technology appraisal guidance 938
2023     WorkSafeBC Efficacy of under-mask beard covers in quantitative fit testing of tight-fitting disposable respirators
2023     WorkSafeBC Platelet rich plasma as treatment for medial epicondylitis
2023     National Institute for Health and Care Excellence (NICE) Targeted-release budesonide for treating primary IgA nephropathy. NICE technology appraisal guidance 937
2023     WorkSafeBC Flotation therapy as treatment for concussions
2023     WorkSafeBC Myalgic encephalomyelitis/chronic fatigue syndrome associated with mRNA COVID-19 vaccination
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: Hereditary Cardiovascular diseases NGS Panel - Evaluation report on the repatriation of an analysis carried out outside of the province of Québec]
2022     Andalusian Health Technology Assessment Area (AETSA) Marcapasos sin cable con sincronía aurículo- ventricular para el tratamiento del bloqueo aurículo-ventricular. Actualización.
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Platelet-rich plasma in certain orthopedic conditions]
2022     Austrian Institute for Health Technology Assessment (AIHTA) ATMPs and gene therapies in development. Horizon scanning – update 2022
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: update of the optimal usage guide on sexually transmitted and blood borne infections – confirmed Mycoplasma genitalium infection]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Embolization or sclerotherapy of pelvic veins in pelvic congestion syndrome]
2022     HTA South [Endovascular valve repair in severe mitral insufficiency]
2022     NIHR Health Technology Assessment programme A pragmatic randomised controlled trial comparing the effectiveness and cost effectiveness of levetiracetam and zonisamide versus standard treatments for epilepsy: a comparison of Standard And New Antiepileptic Drugs (SANAD-II)
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: use of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for the treatment of lung cancer in the Québec context]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: service trajectories and services for at risk or neglected children and their families]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Trastuzumab with pertuzumab in HER2-positive breast cancer]
2022     HTA South [Cardiac Contractility Modulation device treatment in heart failure]
2022     NIHR Health Technology Assessment programme SurgiCal Obesity Treatment Study (SCOTS)
2022     Health Information and Quality Authority (HIQA) High level review of configuration and reform of public health systems in selected countries
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: issues pertaining to the implementation of a clinical decision support system for diagnostic test ordering]
2022     Canadian Agency for Drugs and Technologies in Health (CADTH) Peer support programs for youth mental health
2022     HTA South [Music intervention for adult intensive care patients]
2022     NIHR Health Technology Assessment programme Multicentre UK study of the acetylcholinesterase inhibitor donepezil in early dementia associated with Parkinson's disease (MUSTARDD-PD)
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: needs of children at-risk or in situation of neglect and those of their family]
2022     Center for Drug Evaluation (CDE) The reimbursement coverage decisions and pricing rules for medical devices in Taiwan
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Cryopreservation of eggs and sperm in patients initiating cancer therapy that may affect fertility]
2022     Canadian Agency for Drugs and Technologies in Health (CADTH) Internet-delivered cognitive behavioural therapy in the treatment of chronic non-cancer pain
2022     HTA South [Allograft in peripheral nerve surgery]
2022     NIHR Health Technology Assessment programme A pragmatic randomised controlled trial and economic evaluation of family therapy vs. treatment as usual for young people seen after second or subsequent episodes of self-harm: the Self-Harm Intervention - Family Therapy (SHIFT) trial
2022     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Promoting mental well-being in children and adolescents]
2022     Penn Medicine Center for Evidence-based Practice (CEP) Patient bias against healthcare providers
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Transient elastography in non-alcoholic fatty liver disease]
2022     HTA South [Conductive education in cerebral palsy]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Stem cell therapy in selected orthopedic conditions]
2022     Canadian Agency for Drugs and Technologies in Health (CADTH) Dapagliflozin for chronic kidney disease
2022     HTA South [Is there a difference in outcome between closing the palate in one or two stages?]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Biofeedback in adults with urinary and/or fecal incontinence]
2022     Canadian Agency for Drugs and Technologies in Health (CADTH) Systemic thrombolysis by alteplase for acute ischemic stroke
2022     HTA South [Blood group matching with genotyping]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Electrosurgical units in surgery]
2022     Canadian Agency for Drugs and Technologies in Health (CADTH) Systemic thrombolysis and endovascular therapy for large vessel occlusion acute ischemic stroke
2022     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Psychological Treatment for Postpartum Depression]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Swallowable gastric balloon in obesity]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [OncotypeDX in breast cancer]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: Vistaseal™ – Intraoperative bleeding]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Coronary intravascular lithotripsy in coronary artery disease]
2022     NIHR Health Technology Assessment programme Plasma exchange and glucocorticoids in anti-neutrophil cytoplasm antibody associated systemic vasculitis: a randomized controlled trial. PEXIVAS
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: perineal and pelvic rehabilitation for the prevention and treatment of pelvic floor dysfunctions – Part 1: Urinary incontinence]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Intensity-modulated radiotherapy for prostate cancer]
2022     Health Information and Quality Authority (HIQA) Catalogue of institutions undertaking COVID-19 horizon scanning
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Optical coherence tomography angiography in vascular eye diseases]
2022     Institute for Clinical and Economic Review (ICER) Medications for obesity management: effectiveness and value
2022     Health Information and Quality Authority (HIQA) Planned public health measures and strategies to limit the impact of COVID-19 surges: an international review
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Ultrasound therapy for scar tissue]
2022     Institute for Clinical and Economic Review (ICER) AMX0035 and oral edaravone for amyotrophic lateral sclerosis
2022     National Institute for Health and Care Excellence (NICE) Cabotegravir with rilpivirine for treating HIV-1. NICE technology appraisal guidance 757
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Advanced lymphoedema: can non-medicinal procedures relieve symptoms?]
2022     NIHR Health Technology Assessment programme Randomised control trial of surveillance and no surveillance for patients with Barrett's oesophagus - BOSS (Barrett's Oesophagus Surveillance Study)
2022     Ontario Health First trimester screening for risk of preeclampsia using a multiple marker algorithm
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: pharmacotherapy in the treatment of obesity]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Diamine oxidase activity test for histamine intolerance]
2022     Institute for Clinical and Economic Review (ICER) Novel agents to prevent chemotherapy-induced neutropenia and other myelosuppressive effects [updated Sept 29, 2023]
2022     National Institute for Health and Care Excellence (NICE) Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy. NICE technology appraisal guidance 758
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: optimal use of immunoglobulin in fertility, cardiology and other indications]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Pembrolizumab for head and neck cancer]
2022     National Institute for Health and Care Excellence (NICE) Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 760